Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Protagonist Therapeutics Inc

Healthcare US PTGX

97.05USD
0.39(0.40%)

Last update at 2026-03-10T20:20:00Z

Day Range

95.4098.21
LowHigh

52 Week Range

27.0060.60
LowHigh

Fundamentals

  • Previous Close 96.66
  • Market Cap2757.58M
  • Volume855908
  • P/E Ratio57.04
  • Dividend Yield-%
  • EBITDA28.05M
  • Revenue TTM207.80M
  • Revenue Per Share TTM3.35
  • Gross Profit TTM 207.80M
  • Diluted EPS TTM0.78

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -127.39300M -125.55100M -64.84500M -77.87800M -39.72300M
Minority interest - - - - -
Net income -123.41300M -122.62700M -66.15000M -77.18700M -38.92400M
Selling general administrative 31.74M 27.20M 18.64M 15.75M 13.70M
Selling and marketing expenses - - - - -
Gross profit 26.58M 27.36M 28.63M 0.23M 30.93M
Reconciled depreciation 3.37M 2.77M 2.56M 2.50M 0.53M
Ebit -134.74200M -125.84500M -64.51600M -80.52100M -42.79600M
Ebitda -131.37300M -125.55100M -63.66200M -77.70900M -42.26900M
Depreciation and amortization 3.37M 0.29M 0.85M 2.81M 0.53M
Non operating income net other 3.98M 0.29M 0.27M 2.81M 2.55M
Operating income -131.37300M -125.84500M -64.51600M -80.52100M -42.26900M
Other operating expenses 157.95M 153.20M 93.14M 80.75M 73.19M
Interest expense 3.37M 2.48M 0.60M 0.17M 0.00000M
Tax provision 0.00000M 0.00000M 1.30M -0.69100M -0.79900M
Interest income 4.06M 0.44M 0.90M 2.81M 2.55M
Net interest income 4.06M 0.44M 0.30M 2.64M 2.55M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -3.98000M -2.92400M 1.30M -0.69100M -0.79900M
Total revenue 26.58M 27.36M 28.63M 0.23M 30.93M
Total operating expenses 157.95M 153.20M 93.14M 80.75M 73.19M
Cost of revenue - - - - 0.00000M
Total other income expense net 3.98M 0.29M -0.32900M 2.64M 2.55M
Discontinued operations - - - - -
Net income from continuing ops -127.39300M -125.55100M -66.15000M -77.18700M -38.92400M
Net income applicable to common shares -127.39300M -125.55100M -66.15000M -77.18700M -38.92400M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 744.73M 357.95M 247.93M 347.69M 324.47M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 4.24M 13.96M 0.04M 0.97M 0.31M
Total liab 69.43M 21.27M 784.68M 47.67M 44.86M
Total stockholder equity 675.29M 336.68M -536.75500M -409.36200M -283.81100M
Deferred long term liab - - - - -
Other current liab 23.69M 19.36M 25.02M 38.62M 21.23M
Common stock 0.00100M 0.00100M - - -
Capital stock 0.00100M 0.00100M 0.00000M 0.00000M 0.00000M
Retained earnings -340.52200M -615.71000M -536.75500M -409.36200M -283.81100M
Other liab - - - - 0.12M
Good will - - - - -
Other assets - - 0.23M 0.23M 0.45M
Cash 97.25M 186.73M 125.74M 123.67M 117.36M
Cash and equivalents - - - - -
Total current liabilities 47.40M 21.27M 31.18M 44.02M 40.24M
Current deferred revenue 18.89M 0.00300M - 1.60M 14.48M
Net debt -86.38300M -185.58600M -122.08800M -117.80700M -111.39900M
Short term debt 0.51M 1.14M 2.52M 2.20M 1.46M
Short long term debt - - - - -
Short long term debt total 10.87M 1.14M 3.66M 5.86M 5.96M
Other stockholder equity 1015.90M 952.49M 0.36M 0.30M -0.02800M
Property plant equipment - - 1.56M 6.73M 1.46M
Total current assets 591.64M 355.58M 237.35M 340.74M 315.61M
Long term investments 140.25M - - 0.00000M 2.00M
Net tangible assets - - 215.61M 300.02M 279.61M
Short term investments 321.66M 154.89M 111.61M 203.24M 188.45M
Net receivables 168.49M 10.33M 0.05M 4.36M 3.51M
Long term debt - - - - -
Inventory - -10.33200M -0.09400M 8.50M 3.98M
Accounts payable 1.61M 0.77M 3.64M 1.60M 3.08M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.08200M -0.10500M -0.35900M -0.29900M 0.03M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - -536.75500M -409.36200M -283.81100M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.23M 0.23M 5.95M 0.23M 0.45M
Deferred long term asset charges - - - - -
Non current assets total 153.08M 2.37M 10.57M 6.96M 8.86M
Capital lease obligations 10.87M 1.14M 3.66M 5.86M 5.96M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 92.26M -14.75900M -90.49400M -52.74300M 2.70M
Change to liabilities -11.50000M -14.26600M 7.74M -1.70100M 7.40M
Total cashflows from investing activities 91.47M -15.86000M -90.96500M -53.71000M 2.21M
Net borrowings 14.55M - 31.52M 9.77M 9.77M
Total cash from financing activities 18.84M 129.92M 247.63M 46.04M 24.11M
Change to operating activities -9.76600M 10.21M 3.28M -1.99500M 3.85M
Net income -127.39300M -125.55100M -66.15000M -77.18700M -38.92400M
Change in cash 2.08M 6.07M 84.35M -49.22700M -23.79600M
Begin period cash flow 123.89M 117.82M 33.47M 82.69M 106.49M
End period cash flow 125.97M 123.89M 117.82M 33.47M 82.69M
Total cash from operating activities -108.13700M -107.86500M -72.48400M -41.52700M -49.94700M
Issuance of capital stock 14.55M 123.83M 255.37M 34.49M 23.18M
Depreciation 3.37M 2.77M 2.56M 2.50M 0.53M
Other cashflows from investing activities - - - -52.74300M 2.70M
Dividends paid - - - - -
Change to inventory - - - - 3.85M
Change to account receivables 1.56M 0.86M -0.99000M -2.16800M -2.77100M
Sale purchase of stock 4.45M 130.11M 216.10M 36.27M 2.44M
Other cashflows from financing activities 4.29M 6.09M 2.79M 11.54M 0.93M
Change to netincome 24.20M 18.10M 8.48M 8.36M 6.92M
Capital expenditures 0.80M 1.10M 0.47M 0.97M 0.49M
Change receivables 1.56M 0.86M 4.33M -2.16800M -2.77100M
Cash flows other operating 4.51M -17.96500M -27.71400M 31.06M -23.30600M
Exchange rate changes - - - - -
Cash and cash equivalents changes 2.17M 6.20M 84.18M -49.20100M -23.61900M
Change in working capital -7.76600M -3.31400M -19.01600M 26.14M -18.01700M
Stock based compensation 24.20M 16.39M 7.90M 8.35M 6.92M
Other non cash items -0.54900M 1.83M 0.78M -0.55700M 0.21M
Free cash flow -108.93200M -108.96600M -72.95500M -42.49400M -50.43300M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
PTGX
Protagonist Therapeutics Inc		 0.39 0.40% 97.05 57.04 26.39 13.27 4.00 10.56 72.86
NVO
Novo Nordisk A/S		 -1.06 2.66% 38.72 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 38.88 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 38.30 8.31% 499.17 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -9.57 1.22% 772.03 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Protagonist Therapeutics Inc

7707 Gateway Boulevard, Newark, CA, United States, 94560

Key Executives

Name Title Year Born
Dr. Dinesh V. Patel Ph.D. CEO, Pres, Sec. & Director 1957
Dr. David Y. Liu Ph.D. Chief R&D Strategy Officer 1950
Dr. Suneel K. Gupta Ph.D. Chief Devel. Officer 1958
Dr. Richard S. Shames Clinical Advisor 1960
Mr. Asif Ali Exec. VP & Chief Financial Officer NA
Mr. Mohammad Masjedizadeh Exec. VP & CTO NA
Mr. Matthew M. Gosling Exec. VP & Gen. Counsel 1971
Ms. Carena Spivey Exec. Director of HR NA
Dr. Ashok Bhandari Ph.D. Sr. VP of Discovery Chemistry & Process Research 1964
Dr. Scott Eric Plevy M.D. Exec. VP and Therapeutic Head of Gastroenterology NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.